Applying Patient-Centered Management Strategies to Immune Thrombocytopenia: Allison Miller Imahiyerobo, APN

Immune thrombocytopenia (ITP) is an acquired immune-mediated disorder defined as a peripheral blood platelet count <100 x 109/L with no known cause. In this excerpt of the transcript from her nursing continuing professional development (NCPD)–approved activity, Immune Thrombocytopenia: Evolving Treatment Paradigms and Patient-Centered Care, Allison Miller Imahiyerobo, APN, an advanced practice nurse at the Hematology and Oncology Physicians of Englewood, discusses the pathogenesis of ITP, eme...
Continue reading

Sacituzumab Govitecan for Advanced Urothelial Cancer: Petros Grivas, MD, PhD

Recently, the FDA granted accelerated approval to sacituzumab govitecan (Trodelvy®, Immunomedics), an antibody-drug conjugate, for patients with locally advanced or metastatic urothelial cancer whose disease progressed following treatment with platinum-containing chemotherapy and a programmed cell death protein 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor. In this interview with Oncology Data Advisor, Dr. Petros Grivas, Associate Professor and Clinical Director of the Genitourinary Cance...
Continue reading

Camrelizumab for Advanced Squamous Non-Small Cell Lung Carcinoma: Caicun Zhou, MD, PhD

Recently, the results of a phase 3 trial on camrelizumab were published in the Journal of Thoracic Oncology and presented at the European Lung Cancer Virtual Congress 2021. Camrelizumab was studied in the randomized, double-blind, multicenter trial as a treatment for advanced squamous non-small cell lung carcinoma (NSCLC). Patients with stages IIIB-IV squamous NSCLC were treated with carboplatin plus paclitaxel with camrelizumab or placebo in the first-line setting. Compared with those who recei...
Continue reading

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Nina Shah, MD

Recently, the FDA approved idecabtagene vicleucel (Abecma®, Bristol Myers Squibb) for patients with relapsed or refractory multiple myeloma who have already been treated with four or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. The approval was based on KarMMa, a phase 2 trial that confirmed the efficacy and safety of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. In this interview, one of...
Continue reading

Sacituzumab Govitecan for Triple-Negative Breast Cancer: Aditya Bardia, MD

Recently, the FDA granted regular approval to sacituzumab govitecan (Trodelvy®, Immunomedics, Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously been treated with two or more systemic therapies, at least one of them for metastatic disease. The FDA had previously granted accelerated approval to sacituzumab govitecan based on the results of the phase 1/2 IMMU-132-01 study (NCT01631552); the phase 3 ASCENT study (NCT02574455)...
Continue reading

Melphalan Flufenamide for Multiple Myeloma: Paul Richardson, MD

Melphalan flufenamide, a newly approved peptide-drug conjugate for multiple myeloma, specifically targets chemotherapy to tumor cells like a warhead on a guided missile. In the following interview, Dr. Paul Richardson, the Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, discusses the use of melflufen (Pepaxto®, Oncopeptides AB) for multiple myeloma. Melflufen has its base in melphalan and the old technolo...
Continue reading

Pembrolizumab for Esophageal or Gastroesophageal Junction Carcinoma: Ken Kato, MD, PhD

Recently, the FDA approved pembrolizumab (Keytruda®, Merck Sharp & Dohme Corp.) in combination with platinum/fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal junction (GEJ) carcinoma who do not qualify for surgical resection or definitive chemoradiation. The approval was based on the results of KEYNOTE-590, a phase 3 trial that demonstrated significant improvements in progression-free survival and overall survival for patient...
Continue reading

Breast Cancer Metastases and Survival Outcomes: Wenbin Zhou, MD, PhD

Approximately 3%–8% of patients with newly diagnosed breast cancer have synchronous distant metastases, which are associated with a poor prognosis. Because therapeutic strategies are guided by the status of lymph node metastases, accurate assessment is necessary in order to select the appropriate treatment for different patients. In a study recently published in JAMA Network Open, a team of investigators found that patients with distant metastases experienced significantly worse survival compare...
Continue reading

Nivolumab/Cabozantinib for Renal Cell Carcinoma: David Braun, MD, PhD, and Wenxin (Vincent) Xu, MD

Recently, the results of a phase 3 trial on nivolumab/cabozantinib were published in the New England Journal of Medicine. The study (CheckMate 9ER) compared the efficacy and safety of nivolumab/cabozantinib with those of sunitinib in adult patients with previously untreated advanced clear cell renal cell carcinoma (RCC). The trial results demonstrated that nivolumab/cabozantinib has significant benefits over sunitinib in this patient population. In this interview with Oncology Data Advisor, Dr. ...
Continue reading

Lorlatinib for Metastatic ALK-Positive Non-Small Cell Lung Cancer: Todd Bauer, MD

Recently, the FDA granted approval to lorlatinib (Lorbrena®, Pfizer, Inc.) for the treatment of patients with anaplastic lymphoma kinase (ALK)–positive non-small cell lung cancer. This subset of lung cancers defined by their chromosomal rearrangements of the ALK gene are highly sensitive to small-molecule ALK tyrosine kinase inhibitors (TKIs). Lorlatinib is a novel third-generation small-molecule ALK TKI that was designed to cross the blood-brain barrier in an effort to better treat patients who...
Continue reading

Acupuncture for Managing Chronic Musculoskeletal Pain in Cancer Survivors: Jun Mao, MD, MSCE

Nearly 50% of cancer survivors are undertreated for chronic pain, a condition which negatively impacts cancer-related outcomes, physical function, and quality of life. Due to the challenges of the opioid crisis, non-pharmacologic alternatives for pain management in cancer survivors are greatly needed. In the randomized PEACE trial, results of which were recently published in JAMA Oncology, investigators found that patients receiving electroacupuncture and auricular acupuncture experienced signif...
Continue reading

Diagnosing Myelodysplastic Syndromes With David Steensma, MD, FACP; Reza Nejati, MD; and Ilene Galinsky, BSN, MSN, ANP-C

A complex group of heterogenous hematopoietic disorders, myelodysplastic syndromes (MDS) often go unrecognized and undiagnosed. Accurate diagnosis and risk assessment for this condition require a myriad of tests and an in-depth evaluation of symptoms. In this excerpt from their continuing medical education (CME)/nursing continuing professional development (NCPD) virtual tumor board entitled Diagnosis and Management of Myelodysplastic Syndromes, Dr. David Steensma, Dr. Reza Nejati, and Ms. Irene ...
Continue reading

Axicabtagene Ciloleucel for Follicular Lymphoma: Julio Chavez, MD

Recently, the FDA approved axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. The approval was based on results from ZUMA-5, a phase 2 trial in which axicabtagene ciloleucel demonstrated a high rate of efficacy. In this interview, one of the study investigators, Julio Chavez, MD, of the Moff...
Continue reading

Managing Treatment-Related Adverse Effects of Multiple Myeloma: Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN

Multiple myeloma is a cancer of the bone marrow plasma cells that causes the overproduction of monoclonal immunoglobulins, which can lead to organ damage. In this excerpt of the transcript from her nursing continuing professional development (NCPD)-approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care, Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN, a nurse practitioner at the Cleveland Clinic Taussig Cancer Institute, discusses strateg...
Continue reading

Tirbanibulin for Actinic Keratosis: George Martin, MD

Recently, the results of two phase 3 trials on tirbanibulin were published in the New England Journal of Medicine. Tirbanibulin was studied in two identically designed double-blind trials as a treatment for actinic keratosis, a precursor of cutaneous squamous-cell carcinoma. Adults with actinic keratosis lesions on their face or scalp received either tirbanibulin 1% ointment or placebo once daily for five consecutive days. Compared with those receiving placebo, patients who received tirbanibulin...
Continue reading

Enfortumab Vedotin for Urothelial Carcinoma: Thomas Powles, MD, MBBS, MRCP

For patients with locally advanced or metastatic urothelial carcinoma, treatment options are limited after progression on chemotherapy and immune checkpoint inhibitors, and survival rates remain low. In the phase 3 EV-301 trial, results of which were recently presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, enfortumab vedotin demonstrated promising efficacy in this patient population. In this interview with Oncology Data Advisor, Dr. Thomas Powles, D...
Continue reading

Cemiplimab for First-line Treatment of Advanced Non-Small Cell Lung Cancer: Ahmet Sezer, MD

Recently, the FDA granted approval to cemiplimab-rwlc (Libtayo®, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with advanced non-small lung cancer cell (NSCLC) whose tumors express programmed death ligand 1 (PD-L1) in at least 50% of their cells and whose tumors do not have aberrations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or C-ROS oncogene 1 (ROS1). In this interview, Ahmet Sezer, MD, Professor in the Department of Medical Onco...
Continue reading

Shifting Paradigm in Treating Metastatic Prostate Cancer: Judd W. Moul, MD, FACS

The management of metastatic prostate cancer has undergone a paradigm shift over the last few years. Landmark trials including CHAARTED and STAMPEDE have provided evidence for using therapies that were previously reserved for castration-resistant prostate cancer for patients with hormone-sensitive prostate cancer. In this excerpt of the transcript from his continuing medical education (CME)-approved activity, Clinical Updates and Expert Guidance in Prostate Cancer, Dr. Judd Moul, a urologist at ...
Continue reading

Evaluating Symptoms and Treatment Options for Myelofibrosis: Alice Lynn, ANP, and Dawn Urbanovsky, RN, BSN, OCN®

Myelofibrosis, a myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, and extramedullary hematopoiesis, is a very challenging disease to treat, with patients experiencing progressive symptoms that can negatively impact their quality of life. In this excerpt of the transcript from their nursing continuing professional development (NCPD)-approved activity, Nursing Management of Myelofibrosis: Controlling Symptoms and Optimizing Patient Quality of Life, Alice Lynn, ANP, an...
Continue reading

Cemiplimab Approval for Locally Advanced/Metastatic Basal Cell Carcinoma

Recently, the FDA granted approval to cemiplimab (Libtayo®, Regeneron Pharmaceuticals) for the treatment of patients with locally advanced or metastatic basal cell carcinoma (BCC) who were previously treated with a hedgehog pathway inhibitor (HHI) or who are ineligible for HHI therapy. In this interview, Karl Lewis, MD, Professor of Medical Oncology at the University of Colorado Anschutz Medical Campus and one of the investigators of Study 1620 (NCT03132636), on which the approval was based, spe...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.